EB
EBOSY.US EBOS Group Limited
- Market cap
- USD 2.37B
- P/E
- 14.6x
- P/B
- 1.25x
- ROE
- 8.0%
- Dividend yield
- 6.22%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is EBOSY.US undervalued?
Graham numberEBOSY.US trades 9.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EBOS Group Limited fundamental analysis
No fundamental analysis for EBOS Group Limited yet.
EBOS Group Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EBOS Group Limited
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through the Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; pharmacy data, consumer loyalty, and analytics services; and health communications, programs, and consultancy services. It also…
Full company profileEBOS Group Limited financial statements
EBOS Group Limited annual financial statements (NZD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 7.27B | 7.00B | 6.93B | 9.38B | 9.21B | 10.8B | 12.2B | 13.1B | 12.2B | 13.2B |
| Gross Profit | 719M | 792M | 809M | 987M | 994M | 1.25B | 1.56B | 1.63B | 1.63B | 936M |
| Operating Income | 210M | 218M | 228M | 265M | 296M | 364M | 451M | 481M | 421M | 370M |
| EBITDA | 226M | 252M | 253M | 322M | 355M | 401M | 564M | 589M | 542M | 546M |
| Net Income | 127M | 138M | 138M | 163M | 186M | 214M | 257M | 271M | 214M | 220M |
| EPS | 3.34 | 3.62 | 3.59 | 2.02 | 4.53 | 4.83 | 5.38 | 5.63 | 4.33 | 4.27 |
| Balance Sheet | ||||||||||
| Total Assets | 3.06B | 3.00B | 3.20B | 3.72B | 3.95B | 6.36B | 6.44B | 6.72B | 7.24B | 7.82B |
| Total Liabilities | 1.96B | 1.88B | 1.96B | 2.42B | 2.55B | 4.56B | 4.14B | 4.31B | 4.53B | 5.12B |
| Shareholders' Equity | 1.08B | 1.19B | 1.24B | 1.31B | 1.41B | 2.27B | 2.44B | 2.44B | 2.72B | 2.75B |
| Cash & Short-term Investments | 155M | 150M | 167M | 243M | 169M | 356M | 212M | 216M | 183M | 239M |
| Total Debt | 569M | 584M | 532M | 813M | 681M | 1.65B | 1.28B | 1.64B | 1.61B | 1.90B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 137M | 176M | 121M | 230M | 296M | 262M | 396M | 342M | 416M | 341M |
| Capital Expenditure | 35.8M | 63.3M | 34.2M | 29.4M | 76.7M | 86.2M | 95.2M | 94.1M | 50.1M | 128M |
| Free Cash Flow | 101M | 113M | 84.3M | 201M | 220M | 176M | 301M | 248M | 366M | 213M |
| Ratios | ||||||||||
| ROE | 11.7% | 11.5% | 11.1% | 12.5% | 13.1% | 9.4% | 10.5% | 11.1% | 7.9% | 8.0% |
| ROA | 4.1% | 4.6% | 4.3% | 4.4% | 4.7% | 3.4% | 4.0% | 4.0% | 3.0% | 2.8% |
| Net Profit Margin | 1.7% | 2.0% | 2.0% | 1.7% | 2.0% | 2.0% | 2.1% | 2.1% | 1.8% | 1.7% |
| Debt to Equity | 0.53x | 0.49x | 0.43x | 0.62x | 0.48x | 0.73x | 0.53x | 0.67x | 0.59x | 0.69x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
EBOS Group Limited dividends
- Dividend yield
- 6.22%
- Forward dividend
- 1.41 USD
- Payout ratio
- 56.9%
- Ex-dividend date
- Aug 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | NZD 125M | 2.43 | 56.9% |
| 2025 | NZD 136M | 2.76 | 63.7% |
| 2024 | NZD 156M | 3.24 | 57.5% |
| 2023 | NZD 176M | 3.69 | 68.6% |
| 2022 | NZD 162M | 3.67 | 76.1% |
| 2021 | USD 125M | 3.06 | 67.5% |
| 2020 | USD 112M | 1.39 | 68.8% |
| 2019 | USD 99.9M | 2.61 | 72.6% |
| 2018 | USD 92.6M | 2.44 | 67.3% |
| 2017 | USD 90.5M | 2.39 | 71.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns EBOS Group Limited
Ownership data of EBOS Group Limited is not available yet.
EBOS Group Limited company profile
- Company name
- EBOS Group Limited
- Ticker
- EBOSY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 5,009
- Fiscal year end
- June
- Address
- 737 Bourke Street, Docklands, VIC, Australia, 3008
- Phone
- 61 3 9918 5555
- Website
- ebosgroup.com
About EBOS Group Limited
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through the Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; pharmacy data, consumer loyalty, and analytics services; and health communications, programs, and consultancy services. It also offers community-based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five-step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. In addition, the company offers healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; dog and cat food, and treats; and surgical devices and medical consumables. Further, it provides pet nutrition, treats, clean-up, and grooming products and accessories; supplies pet medicines and other products to veterinary clinics and specialty retailers; manufactures and supplies dog rolls; and wholesales veterinary products. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.
EBOS Group Limited management
10- Mr. Adam Luke Hall B.Com., BCOMM, L.L.B., LLB (HONS), M.B.A.Chief Executive Officer · born 1975
- Mr. Alistair GrayChief Financial Officer
- Mr. Leonard HansenChief Accountant & Chief Risk Officer
- Mr. Mithran NaikerChief Information Officer
- Mr. Cameron SinclairHead of Investor Relations
- Ms. Janelle CainGeneral Counsel
- Ms. Jacinta McCarthyExecutive General Manager of Human Resources
- Mr. Simon BundeExecutive General Manager of Strategic Operations, ESG & Innovation
- Mr. Grant VineyChief Executive Officer of EBOS Animal Care
- Ms. Kristine JamesCEO of Medical Technology